HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemp Industry Appeals To National Governments Over CBD Narcotic Classification

Executive Summary

Hemp industry groups in France and Germany are separately appealing to their national governments to intervene in the European Commission's attempt to classify CBD as a narcotic rather than novel food.

You may also be interested in...



UN Vote On Cannabis Controls Could Be Crucial To CBD’s Future In EU

Legal experts say the EU already prohibits cosmetic use of CBD sourced from hemp flowers, and it now appears that food supplement use could be held to the same standard. The World Health Organization has recommended changes to the half-century-old international treaty governing narcotic controls, which could help to resolve the situation, but there are reports of UN pushback.

EU CBD Market Under Threat With Narcotic Classification Favored

Leaning towards classifying CBD as a narcotic, the European Commission could dash hopes of a regulated EU market for dietary supplements containing the cannabinoid. 

EMEA Round-Up: Bayer Strikes Egypt Deals, Orkla Acquires NutraQ, Uriach Grabs Sidroga

Round-up of the latest news across EMEA, including two deals for Bayer in Egypt and Saudi Arabia; Orkla's acquisition of NutraQ; and Uriach's deal for Sidroga.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel